Keep in touch


Negotiating public-health driven licences is the core work of the Medicines Patent Pool, and is based on an assessment of needed HIV medicines from both a clinical perspective and in terms of where patents may post barriers to generic competition.

To date, the MPP has secured licences for eight WHO preferred first-line and second-line treatments for both adults and children over three years of age: atazanavir (ATV), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), elvitegravir (EVG), cobicistat (COBI), abacavir (ABC) for paediatric use, darunavir (DRV) and dolutegravir (DTG) for both paediatric and adult care.

The MPP has also sub-licensed to generic manufacturers, who are already beginning to produce and supply HIV medicines at a lower cost. As of January 2014, the Pool had signed six sub-licensing agreements: to Aurobindo Pharma Limited, Emcure Pharmaceuticals, Hetero Labs, Laurus Labs, Shasun Pharma Solutions and Shilpa Medicare.

This page is also available in: French, Spanish